Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole

Mario Valenzano Menada, Sergio Costantini, Melita Moioli, Stefano Bogliolo, Andrea Papadia, Simone Ferrero, Maria Cristina Dugnani

Research output: Contribution to journalArticle

Abstract

Evaluation of endometrial thickness by transvaginal ultrasonography (TVUS) in postmenopausal estrogen receptor positive breast cancer patients treated with anastrozole after tamoxifen therapy. This study included 70 postmenopausal estrogen receptor positive breast cancer patients who switched to anastrozole after tamoxifen; patients had endometrial thickness >4 mm and no endometrial malignancy. Endometrial thickness was measured after anastrozole treatment. Endometrial thickness during anastrozole therapy was lower than after tamoxifen therapy (p <0.001); the mean reduction in endometrial thickness was 4.5 mm (±3.0). Cystic endometrial appearance was more frequent in patients under tamoxifen than in those under anastrozole (p <0.001). Duration of tamoxifen therapy was not correlated to the endometrial thickness at the time of its suspension. Duration of tamoxifen therapy and endometrial thickness at the time of tamoxifen suspension was correlated to the relative reduction of endometrial thickness during anastrozole therapy. Anastrozole reverses tamoxifen-induced increased endometrial thickness and sonographic endometrial cystic appearance.

Original languageEnglish
Pages (from-to)631-636
Number of pages6
JournalBreast
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 2008

Keywords

  • Adjuvant treatment
  • Anastrozole
  • Breast cancer
  • Endometrial pathology
  • Endometrial thickness
  • Tamoxifen
  • Transvaginal ultrasonography

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole'. Together they form a unique fingerprint.

  • Cite this